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Objective: Tobacco smoking significantly impacts clozapine blood
levels and has substantial implications on individual efficacy and safety
outcomes. By investigating differences in clozapine blood levels in
smoking and non-smoking patients on clozapine, we aim to provide
guidance for clinicians how to adjust clozapine levels for patients on
clozapine who change their smoking habits.
Methods: We conducted a meta-analysis on clozapine blood levels,
norclozapine levels, norclozapine/clozapine ratios, and concentration to
dose (C/D) ratios in smokers and non-smokers on clozapine. Data were
meta-analyzed using a random-effects model with sensitivity analyses
on dose, ethnic origin, and study quality.
Results: Data from 23 studies were included in this meta-analysis with 21
investigating differences between clozapine blood levels of smokers and
non-smokers. In total, data from 7125 samples were included for the
primary outcome (clozapine blood levels in ng/ml) in this meta-analysis.
A meta-analysis of all between-subject studies (N = 16) found that
clozapine blood levels were significantly lower in smokers compared with
non-smokers (Standard Mean Difference (SMD) 0.39, 95% confidence
interval (CI) 0.55 to 0.22, P < 0.001, I2 = 80%). With regard to the
secondary outcome, C/D ratios (N = 16 studies) were significantly lower
in the smoker group (n = 645) compared with the non-smoker group
(n = 813; SMD 0.70, 95%CI 0.84 to0.56, P < 0.00001, I2 = 17%).
Conclusion: Smoking behavior and any change in smoking behavior is
associated with a substantial effect on clozapine blood levels.
Reductions of clozapine dose of 30% are recommended when a patient
on clozapine stops smoking. Reductions should be informed by
clozapine steady-state trough levels and a close clinical risk-benefit
evaluation.
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Summations
• Smoking behavior significantly reduces clozapine blood levels.
• When a patient stops smoking, reductions of clozapine dose of 30% are recommended.
Considerations
• Besides smoking behavior, other factors impacting clozapine blood levels (e.g., age, gender, comedi-
cation with clinically relevant CYP1A2-interaction, caffeine intake, Cytochrome P-polymorphisms,
ethnic origin) should be accounted for in future studies and, more importantly, measurement of
clozapine blood levels has to be implemented in future studies to provide further evidence for a safe
and efficacious use of clozapine.
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Clozapine is the most effective antipsychotic agent
for treatment-resistant schizophrenia (TRS) (1,2).
Clozapine is one of the few antipsychotics where
therapeutic level monitoring is used, with levels
above the maximum threshold (1000 ng/ml) being
associated with an increased risk of seizures (3). In
clinical practice, pseudo-resistance to clozapine may
occur as a result of blood levels below the minimum
threshold definition (350 ng/ml) and there is an
association between clozapine blood levels and
response (4). Cytochrome P450 (CYP) 1A2
(CYP1A2) is the major clozapine metabolic enzyme
and is responsible for approximately 70% of cloza-
pine’s metabolism (5). Clozapine is metabolized to
its primary metabolite norclozapine (5). In this
regard, polycyclic aromatic hydrocarbons generated
by tobacco smoking induce the activity of CYP1A2
(6) which leads to increased clozapine metabolism.
Rates of smoking are up to five times higher
among people with schizophrenia compared to the
general population, with smoking rates among
people with schizophrenia as high as 60% (7). A
daily consumption of 7–12 cigarettes may be suffi-
cient for maximum induction of clozapine metabo-
lism (8). Beginning smoking is therefore a clinically
relevant risk for relapse and inadequate response
to clozapine treatment (9) and smoking cessation
among clozapine users can induce severe clozapine
intoxication (10). Ethnicity (Asian heritage)
(11,12), gender (13), age (13-15), CYP-polymor-
phisms (16), caffeine (17), and comedication with
clinically relevant CYP1A2-interaction (9) can also
influence clozapine blood levels through the CYP-
450 system. In this context, for example, people of
Asian heritage are presumed to need a lesser cloza-
pine dose compared with Caucasian or American
populations (12,18) which might be due to a rela-
tively reduced CYP1A2 activity (11). On a similar
note, the clinical relevance of CYP1A2 can be
observed in smoking patients after transition to
electronic cigarettes, where the termination of
CYP1A2 induction also induces a clinically rele-
vant increase in clozapine blood levels (19).
Concentration to dose (C/D) ratio is a measure
of clozapine clearance and higher ratios—indicat-
ing lower clearance—are associated with females,
non-smokers, Asians, genetic poor metabolizers,
CYP-inhibitors, obesity, inflammation and possi-
bly with renal impairment and pregnancy (18),
whereas lower ratios indicate lack of adherence or
are associated with males, smokers, non-Asians,
and CYP-inducers (18).
In summary, there is a lack of clarity in the
available literature as to how great an influence
changes in smoking habit can have on clozapine
blood levels. To guide clinical care of people trea-
ted with clozapine, and to assist in averting sub- or
supra-therapeutic clozapine levels and their associ-
ated deleterious effects, we conducted a systematic
review and meta-analysis of the impact on changes
in smoking habit on clozapine blood levels among
people on clozapine. Our primary outcome of
interest was impact on clozapine blood levels, with
secondary outcomes of impact on clozapine to C/
D ratios, norclozapine/clozapine ratios, and nor-
clozapine levels. We planned sensitivity analyses
and meta-regression analyses on other factors
which influence clozapine metabolism including
ethnicity, age, and gender, to assist in clarifying
the role of potential confounders, if any.
Subtitle
To investigate the impact of smoking behavior on
clozapine blood levels and clozapine concentration
to dose ratios in order to provide guidance for clin-
icians how to manage patients on clozapine who
smoke or stop smoking.
Methods
The methods are based on the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) (20). This study was registered with PROS-
PERO (registration number CRD42020185579), an
international database of prospectively registered sys-
tematic reviews.
Searches
Systematic searches were conducted of publica-
tions indexed in PubMed, EMBASE, and Psy-
cINFO using the search terms (level OR levels OR
concentration OR concentrations OR ratio OR
ratios) AND (blood OR serum OR plasma) AND
(clozapin* OR clozaril OR zaponex OR denzapin*
OR clopine OR norclozapine OR desmethylcloza-
pine). The abstracts and titles of articles identified
through electronic searches were independently
screened by two reviewers (EW, LM). Publications
in all languages were considered for inclusion.
Inclusion criteria
Studies were included if they reported information
on mean (and SD) of clozapine blood levels OR C/
D ratios for people with psychiatric disorders who
were smoking and not smoking in cohort studies,
case–control studies or randomized or non-ran-
domized controlled trials.
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Exclusion criteria
Case reports and case series were excluded.
Assessment of reporting strength
As all studies suitable for inclusion were observa-
tional studies, we used a modified Newcastle-
Ottawa Quality Assessment Scale (21) for assess-
ment of quality. The maximum score was 5, and
studies with score of at least 3 were rated as high-
quality studies. We considered the following
domains: representativeness of the sample, sample
size, comparability between smokers and non-
smokers, ascertainment of clozapine blood levels
(outcome) and quality of descriptive statistics
(quality scores are provided in Table S2, modified
Newcastle-Ottawa Quality Assessment Scale is
provided in Appendix S1).
Data extraction
Two reviewers (EW, LM) independently extracted
the data into an electronic spreadsheet and dis-
agreements were resolved by joint examination of
the papers. The following data were extracted:
1. Sample size of subjects on clozapine (smokers and
non-smokers)
2. Mean (and SD) clozapine blood levels in both groups
(ng/ml)
3. Mean (and SD) clozapine dose in both groups (in
mg/day)
4. Type of comparison (within-subject or between-sub-
ject comparisons between the two groups)
The following characteristics of each study were
recorded where possible and if available, both for
male and female participants in both groups sepa-
rately:
1. Mean age of subjects in both groups
2. Ratio male:female in both groups
3. Clozapine blood levels and clozapine doses for male
and female participants
4. Whether data collection was prospective or retro-
spective
5. Inpatient or outpatient status of subjects
6. Amount of smoking in the smoking group
7. Concentration to dose (C/D) ratio in both groups
8. Norclozapine levels in both groups
9. Norclozapine to clozapine ratios in both groups
Data synthesis and analysis
The primary outcome was the clozapine blood
level (in ng/ml) in the smoker and non-smoker
group. Where adequate quantitative data were not
reported, corresponding authors were contacted to
provide means and SDs. Where confidence inter-
vals were reported, these were converted to SD
using the Cochrane Handbook formula (17).
Included studies were divided into between-subject
studies and within-subject studies. Between-subject
studies compared data from subjects on clozapine
divided into smokers and non-smokers, whereas
within-subject studies investigated effects within
the same individuals as smokers and then non-
smokers. Meta-analyses were conducted using
RevMan (version 5.3), and meta-regression analy-
ses were conducted using Comprehensive Meta-
Analysis (version 3.3). We assessed heterogeneity
using the I2 statistic, a measure that does not
depend on the number of studies in the meta-anal-
ysis and hence has greater power to detect hetero-
geneity when the number of studies is small. I2
provides an estimate of the percentage of variabil-
ity due to heterogeneity rather than chance alone.
An estimate of 50% or greater indicates possible
heterogeneity, and scores of 75–100% indicate
considerable heterogeneity. Given the observa-
tional nature of primary studies and expected high
rates of heterogeneity, a random-effects model was
used for all the analyses. A significance level of
a < 0.05 was applied for all analyses.
Subgroup and sensitivity analyses
Subgroup analyses were undertaken for between-
subject studies for high-quality (as defined by ≥3
out of 5 points on the modified Newcastle-Ottawa
Scale) vs. low-quality studies, male populations,
female populations, and studies with people from
Asian origin vs. studies with people not from Asian
origin. Meta-regression analyses were performed
for between-subject studies for clozapine blood
levels and the moderators (i) difference in clozap-
ine dose between smokers and non-smokers (ii)
proportion of male smokers and (iii) proportion of
male non-smokers (iv) age (smokers) and (v) age
(non-smokers).
Publication bias
Where meta-analyses included at least 10 studies,
publication bias was tested using funnel plot asym-
metry with Kendall’s Tau, where low P-values sug-
gest publication bias. A threshold of 10 for funnel
plots was chosen in accordance with the recom-
mendations from the Cochrane Handbook (22).
Results
In total, 7600 articles were independently screened
on title/abstract level and 113 articles on full-text
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level by two reviewers. A total of 90 articles were
excluded at full-text review (see Table S1 for list of
excluded studies with reasons), with 23 articles
(8,16,23-43) included in the meta-analysis (see
Fig. 1, List of included studies see Table 1).
Twenty-one articles (8,16,23-31,34-43) investigated
differences between smokers and non-smokers as
between-subject analyses and two studies (32,33)
compared differences as within-subject analyses
change of blood levels among smokers after insti-
tutional smoking ban). In total, data from 7125
samples were included for the primary outcome
(clozapine blood levels in ng/ml) in this meta-anal-
ysis. Of these, 4925 were from smokers and 2185
from non-smokers (N = 21, between-subject
analyses) and 15 were smokers and subsequent
non-smokers (N = 2, within-subject analyses). 18
out of 23 studies were performed exclusively in
schizophrenia-spectrum populations, with the
remaining five additionally including (a small
amount of) patients with bipolar disorder (26,33),
unspecified psychiatric disorders (38,43), and psy-
chiatric disorders except organic disorders (27).
Between-subject analyses
Clozapine blood levels. The 16 studies (8,23,25-
31,34,35,37-39,41,42) reported on blood levels for
samples of smokers (n = 4925) and non-smokers
(n = 2185). Overall, study quality was moderate,
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Embase (1988 to week 14, 2020) 
(n=6593) and 
PsycInfo (no filter) (n=971)
Fig. 1. PRISMA-Flowchart (study selection process). Systematic literature search according to Moher et al. (20). [Colour figure can
be viewed at wileyonlinelibrary.com]
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with 6/16 rated as high-quality (23,26,31,35,39,41)
and 10 as low/moderate-quality according to mod-
ified Newcastle-Ottawa Rating Scale (see
Appendix S1). Four studies were retrospective
(23,26,27,41) and 12 prospective (8,25,28-31,34,37-
39,42). All except three studies (26,27,38) were
exclusively covering people with schizophrenia-
spectrum disorders. From these 16 studies, four
(28-30,41) were restricted to people of Asian ori-
gin.
A meta-analysis of all between-subject studies
(N = 16) found that clozapine blood levels were
statistically significantly lower by more than a
third in smokers compared with non-smokers
(Standard Mean Difference (SMD) 0.39, 95%
confidence interval (CI) 0.55 to 0.22,
P < 0.00001, I2 = 80%; see Figure 2). On sensitiv-
ity analyses, when restricted to the six high-quality
studies (n = 4393 samples in the smoker group and
n = 1583 samples in the non-smoker group),
results remained significant (SMD 0.29, 95%CI
0.51 to 0.07, P < 0.009; see Figure S1). Neither
the difference between clozapine dose for smokers
or non-smokers (Q = 0.04, df = 1, P = 0.848) nor
age of smokers or non-smokers significantly
impacted the effect size in a meta-regression
(Q = 0.36, df = 2, P = 0.834).
Nevertheless, a higher proportion of male par-
ticipants among smokers and non-smokers had
increased the effect size (Q = 18, df = 2,
P = 0.0001). Scatterplots for moderator variables
are displayed in the Figures S19-S25. There was no
evidence of publication bias (s = 0.05, P = 0.77,
see Table S3).
When restricted to the five studies conducted
among people with Asian origin, results were not
significant (SMD 0.43, 95% CI 0.97 to 0.11,
P = 0.12). However, there was one outlier study
(41) from Asia where levels in the smoker group
were reported to be higher than in the non-smoker
group (see Figure S2). When this study was
removed (N = 4 studies, 75 smokers vs. 127 non-
smokers), results were significant (SMD 0.63,
95%CI 1.05 to 0.21, P = 0.003). When the
analysis was restricted to non-Asian studies, results
were also significant (SMD 0.39, 95%CI 0.58
to 0.21, P < 0.0001; see Figure S3).
There was insufficient relevant data to conduct
sensitivity analysis or meta-regression for gender.
Clozapine Dose. Sixteen studies reported on asso-
ciated clozapine doses (in mg per day) for samples
of smokers (n = 4925) and non-smokers
(n = 2185). Doses were significantly higher in the
smoker group compared to the non-smoker group
(SMD 0.22, 95%CI 0.07 to 0.36, P < 0.003) with
high between-sample heterogeneity (P < 0.00001,
I2 = 71%; see Figure S4). When analyses were
restricted to the six high-quality studies, results
were not significant (SMD 0.14, 95%CI 0.03 to
0.31, P = 0.11) between samples of smokers
(n = 4393) and non-smokers (n = 1583; see Fig-
ure S5). When restricted to studies among people
with Asian origin (N = 4), doses were significantly
higher in smokers (n = 125) compared to non-
smokers (n = 218; SMD 0.33, 95%CI 0.01 to 0.65,
P = 0.04; see Figure S6). When restricted to non-
Asian studies, results were similar for associated
doses between samples of smokers (n = 4800) and
non-smokers (n = 1967; SMD 0.18, 95%CI 0.03 to
0.33, P = 0.02; see Figure S7). There were not
enough data for additional analyses (e.g., male vs.
female comparisons).
Norclozapine/Clozapine Ratio. Five studies
(23,24,28,30,35) reported on norclozapine/clozap-
ine ratios for samples of smokers (n = 4232) and
non-smokers (n = 1460), with no significant differ-
ence in norclozapine/clozapine ratios between the
two groups (SMD 0.00, 95%CI 2.04 to 2.03,
P = 1.00; see Figure S8). There were not enough
data for additional analyses.
Norclozapine blood levels. Seven studies (23,28-
30,34,35,38) reported on norclozapine blood levels
for samples of smokers (n = 4321) and non-smok-
ers (n = 1643). There was no significant difference
between the two groups (SMD 0.08, 95%CI
0.19 to 0.04, P = 0.18) with low/moderate
heterogeneity (P = 0.12, I2 = 39%; see Figure S9).
When restricted to five non-Asian studies, results
remained non-significant between samples of
smokers (n = 4263) and non-smokers (n = 1512;
SMD 0.05, 95%CI 0.16 to 0.07, P = 0.44; see
Figure S10). There were not enough data for addi-
tional analyses.
C/D ratio. Eight studies (8,16,23,24,27,36,40,43)
reported on C/D ratios for smokers (n = 645) and
non-smokers (n = 813). C/D ratios were statisti-
cally significantly lower in the smoker group
(SMD 0.70, 95%CI 0.84 to 0.56,
P < 0.00001) with low between-sample heterogene-
ity (P = 0.28, I2 = 17%; see Figure S11). In a sen-
sitivity analysis restricted to four high-quality
samples, results remained significant between
smokers (n = 140) and non-smokers (n = 349;
SMD 0.58, 95%CI 0.83 to 0.34, P < 0.00001;
see Figure S12). In a sensitivity, analysis restricted
to five samples of people from Asian origin from
one study (36) with n = 138 smokers and n = 432
non-smokers, results remained significant (SMD
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0.59, 95%CI 0.79 to 0.39, P < 0.00001) with
low between-sample heterogeneity (P = 0.39,
I2 = 2%; see Figure S13). When restricted to seven
non-Asian studies, results remained significant
between smokers (n = 507) and non-smokers
(n = 381; SMD 0.78, 95%CI 0.97 to 0.59,
P < 0.00001; see Figure S14). There were not
enough data for additional analyses (e.g., male vs.
female comparisons).
Within-subject analyses
Clozapine blood levels. A meta-analysis of two
within-subject studies (32,33) found significantly
increased levels after transition from smoking sta-
tus (n = 15) to non-smoking status (n = 15; SMD
0.84, 95%CI 1.60 to 0.08, P = 0.03; see Fig-
ure S15). There were insufficient data for further
analyses.
Discussion
This meta-analysis from a total of n = 23 studies
comprising more than 7000 subjects with psychi-
atric disorders represents the most comprehensive
analysis on the relationship of clozapine levels/ra-
tios and smoking to date. We found that clozapine
blood levels are reduced by around a third in
smokers compared with non-smokers. Our analysis
is the first to comprehensively combine and quan-
tify published data on the impact of smoking on
clozapine levels. For patients on clozapine who
smoke and subsequently quit smoking, dosages
should be decreased by 30% and clozapine blood
level analyses should be performed. It is important
to note that the CYP1A2 activity decrease may be
a gradual process over the first three to four days
after smoking cessation (44). Conversely, if
patients start to smoke clozapine blood levels may
fall by 30% resulting in the need to increase the
dose and to monitor blood levels. In this regard,
clinical signs of clozapine underdosing, such as
anxiety, restlessness, and sleep disturbances must
be monitored in patients who commence smoking.
In our analyses, clozapine blood levels were sig-
nificantly lower in smokers. However, there may
be unaccounted for confounding factors. Co-oc-
curring caffeine intake might have increased cloza-
pine blood levels due to CYP1A2 inhibition as
previously observed in the literature (17). Smoking
and caffeine use may co-occur among people with
schizophrenia (45). Thus, differences in blood
levels between smokers and non-smokers might
have been underestimated since none of the
included studies controlled for caffeine consump-
tion. We were not able to conduct sensitivity
analyses for caffeine as these data were not
reported. We were only able to include informa-
tion on other reported relevant CYP-450 interact-
ing comedication.
C/D ratios were significantly lower in smokers in
our analyses and our results remained significant
when analyses were restricted to high-quality stud-
ies or studies from Asian origin. This allows for
adjustment for certain factors associated with CYP
activity such as Asian genetic heritage. However,
impact of other factors associated with influence on
C/D ratios (e.g., gender, poor metabolizer, obesity,
and inflammation) was not able to be controlled for
in our analyses. Furthermore, we were able to
undertake meta-regressions examining the impact
of dose, age, and gender on clozapine blood levels
between smokers and non-smokers. Our findings
regarding the influence of gender on clozapine
blood levels with smoking should be treated with
caution, since only three studies reported blood
levels (33,35,39), one reported C/D ratios (36)
between smokers and non-smokers for male and
female populations separately and one study only
included only one gender (41). In one of the studies
which disaggregated data by gender and smoking
status, only 14% of men were non-smokers (35),
which may have skewed the results. Between-sub-
ject analyses may be biased since the included stud-
ies, with the exception of Lu et al. (30), were not
fixed-dose studies and doses in smokers might have
been increased by the treating clinicians. Thus, the
true difference induced by smoking might be bigger
than estimated, as suggested by within-subject anal-
yses based on limited subject numbers. Further-
more, one study from Rostami et al. reported
samples of smokers and non-smokers, and thus var-
ious samples might be derived from the same
patients increasing the risk of bias.
Our analyses had a high degree of heterogeneity,
and as such our results should be viewed with cau-
tion. We were able to conduct sensitivity analyses
and meta-regression on dose, gender, ethnicity,
and age. There were insufficient data to permit
meta-regression for comedications, smoking quan-
tity, genetics for fast metabolizer, caffeine use or
body weight, since none of the included studies
reported these confounders for smokers and non-
smokers homogenously allowing for meta-analy-
ses. Nevertheless, comedication was considered as
an item in our assessment of reporting strength
and thus high-quality studies excluded clinically
relevant CYP1A2 interacting comedication. Fur-
thermore, seven out of our included studies were
retrospective analyses which may be more prone to
bias than prospective approaches, especially since
data may not be available on medication
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adherence and ascertainment of smoking behavior
is less certain. We attempted to address this
through our sensitivity analysis of study quality.
Ours is the largest meta-analysis on clozapine
blood levels and C/D ratios from a total of four
studies (46). In contrast to the work from Tsuda
et al., we included studies of patients of Asian her-
itage, assessed risk of bias and conducted sensitiv-
ity analyses and meta-regression analyses, if
possible. Based on their meta-analysis on C/D
ratios, Tsuda et al. estimated that if 200 and
400 mg per day of clozapine would be adminis-
tered to smokers, about 100 and 200 mg per day,
respectively, should be administered to non-smok-
ers, based on a SMD C/D ratio of 1.1 (46). In our
analyses, SMD of C/D ratio between smokers and
non-smokers (0.7 ng/ml per mg/day) was lower
than in the one from Tsuda et al. suggesting an
estimated 30% reduction of dose after a patient
stops smoking.
Conclusion
Our meta-analysis confirms that smoking behavior
and any change in smoking behavior is associated
with substantial clinical implications for patients
on clozapine and extends the current knowledge by
providing an evidence-based quantification of
these effects. According to our analyses, reductions
of clozapine dose by 30% are recommended when
a patient on clozapine stops smoking. Neverthe-
less, reductions have to be performed with TDM
of clozapine steady-state trough levels and a clini-
cal risk-benefit evaluation since high variability
between individuals (95% CI in the range of 0.55
to 0.22 in our analyses) has to be expected. Dose
reductions should be combined with instruction of
patient and nurses (for signs of intoxication and
relapse) and a close monitoring of clozapine blood
levels.
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